Image Source: Unsplash

An Introduction

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

The AI-focused Drug Discovery Stocks Portfolio

The 6 AI-focused clinical-stage drug discovery stocks currently trading on Canadian or American stock exchanges are highlighted below, in descending order, for last week (w/e Sept. 13th), the previous week (Sept. 6th) and in August, along with a description of their areas of focus, their market capitalizations, their product pipeline, their prevailing short interest percentage which is a measure of how many investors are betting that a stock’s price will fall further and any news contributing to the price change in the stock:

1. Relay Therapeutics (RLAY): up 21.8% w/e Sept. 13th; down 8.1% w/e Sept. 6th; down 17.4% in August
   • Area of Focus: uses its platform to enhance small molecule therapeutic discovery in targeted oncology and genetic disease indications (see details here)
   • Market Capitalization: $1,230M
   • Pipeline: (see here)
   • Short Interest: 5.6% (down from 6.8% the previous week)
   • Latest News, Analyses and Commentary:
     • Relay Stock Soars on Upbeat Data From Breast Cancer Study
2. AbCellera Biologics (ABCL): up 15.1% w/e Sept. 13th; down 6.6% w/e Sept. 6th; down 21.5% in August
   • Area of Focus: searches for antibodies from natural immune responses which are then outsourced to their partners. (see details here)
   • Market Capitalization: $810M
   • Pipeline: (see here)
   • Short Interest: 6.2%
   • Latest News, Analyses and Commentary:
     • AbCellera Biologics Is A Top Contender Among Canada’s Best Penny Stocks in 2024
3. Recursion Pharmaceuticals (RXRX): up 11.0% w/e Sept. 13th; down 18.7% w/e Sept. 6th; down 11.2% in August
   • Area of Focus: decodes biology by integrating technological innovations to industrialize drug discovery (see details here)
   • Market Capitalization: $1,850M
   • Pipeline: (see here)
   • Short Interest: 9.8% (down from 10.8% the previous week)
   • Latest News, Analyses and Commentary:
     • Recursion Pharmaceuticals: A Very Important AI Stock According to BlackRock
4. Exscientia (EXAI): up 2.7% w/e Sept. 13th; down 11.9% w/e Sept. 6th; up 5.1% in August
   • Area of Focus: designs and develops differentiated medicines for diseases with high unmet patient needs (see details here)
   • Market Capitalization: $650M
   • Pipeline: (see here)
   • Short Interest: 2.9%
   • Latest News, Analyses and Commentary:
     • Exscientia: A Penny Stock That Will Make You a Millionaire
5. Schrödinger (SDGR): up 1.1% w/e Sept. 13th; down 2.5% w/e Sept. 6th; down 5.6% in August
   • Area of Focus: uses its platform to discover novel molecules which it leverages to build a pipeline of its own clinical programs in addition to selling access to its platform to other pharmaceutical firms (see details here)
   • Market Capitalization: $1,510M
   • Pipeline: (see here)
   • Short Interest: 13.2%
   • Latest News, Analyses and Commentary:
     • Schrödinger Among The Best Medical AI Companies
6. Absci Corporation (ABSI): down 3.0% w/e Sept. 13th; down 8.6% w/e Sept. 6th; No Change in August
   • Area of Focus: analyzes drug characteristics that may provide therapeutic benefit. (see details here)
   • Market Capitalization: $443M
   • Pipeline: (see here)
   • Short Interest: 9.9%
   • Latest News, Analyses and Commentary:
     • Absci Second Quarter 2024 Earnings: Misses Expectations

Summary

On average, the 6 constituents in our AI-focused Drug Discovery Stocks Portfolio (averaging $1,082M in market capitalization) went up 5.9% w/e Sept. 13th, down 7.7% w/e Sept. 6th, and down 7.8% in August vs. going up 16.1% during July.

More By This Author:

Cannabis LP Stocks Were +6% Last Week Vs. -10% The Previous Week
Our Quantum Computing Portfolio Was -9.8% Week-Ending September 6th
Our Computer Chips-Related Portfolio Was -12% Week-Ending Sept. 6th